$STRS

Mon: TASE claws back strong early losses

Israel and Iran reportedly agreed to stop hostilities under US pressure, helping the Tel Aviv Stock Exchange rebound from early losses. The TA-35 rose 0.33% to 4,281.85 and TA-125 rose 0.01% to 4,232.14; BlueTech Global fell 0.86% to 696.72. Insurance gained 2.2%; TelBond 60 was flat. Turnover: NIS 4.80b equities, NIS 5.43b bonds. Shekel strengthened to NIS 2.943/$ and NIS 3.39/€.

Original reporting
Published Jun 9, 2026, 12:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 9, 2026, 1:18 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Mon: TASE claws back strong early losses — source image
Decision brief

The 30-second read

$STRSBullishLow
01

Why it matters

The newest concrete fact is the market’s reaction to cease-hostilities clarity; company moves are presented as part of that tape rather than standalone fundamentals.

02

Market read

Useful for gauging intraday risk sentiment and which Tel Aviv sectors/names are trading as proxies, but it contains no new issuer-specific fundamentals.

03

What to watch

The article is a market wrap with no company-specific catalysts; traders should treat moves as correlation trades and wait for follow-through from subsequent sessions or filings.

Relevance 4/10Novelty 2/10Timing: during the Tel Aviv session (morning losses then rebound)

Background

The session is framed around a shift in Israel-Iran hostilities expectations after US pressure, with indices mixed and turnover reported.

Company-level read

Ticker impact

$STRSBullishLow confidence
Context

Strauss Group jumped 4.19%, the biggest rise on the Tel Aviv 35 Index during the market’s recovery from early losses.

Expected impact

Momentum may persist intraday, but reversal risk is elevated without a fundamental trigger.

Evidence & confidence

The article frames the move within the broader market rebound; no new Strauss disclosure.

$ENLTBullishLow confidence
Context

Enlight Renewable Energy rose 1.08% during the rebound, with no separate company-specific development cited.

Expected impact

Limited conviction beyond market beta.

Evidence & confidence

The text provides only an intraday move and macro backdrop.

$ESLTBullishLow confidence
Context

Elbit Systems rose 1.89% as the market recovered on expectations of reduced hostilities between Israel and Iran.

Expected impact

Short-term upside while de-escalation holds; could reverse if security risk returns.

Evidence & confidence

Move is plausibly macro-driven; no Elbit-specific disclosure is included.

$TEVABullishLow confidence
Context

Teva Pharmaceutical rose 2.26% during the rebound after Israel-Iran cease-hostilities clarity under US pressure.

Expected impact

Near-term support if risk sentiment stays constructive.

Evidence & confidence

Only same-day price action is reported; catalyst is macro.

$TSEMBearishLow confidence
Context

Tower Semiconductor fell 4.73% for the biggest drop on the Tel Aviv 35 Index despite the overall market rebound.

Expected impact

Higher volatility/mean-reversion risk; direction depends on whether the selloff is headline- or flow-driven.

Evidence & confidence

The text cites only the intraday decline and macro backdrop, without a TSEM catalyst.

$CAMTBearishLow confidence
Context

Camtek fell 2.33% as the Tel Aviv market was mixed, with some names diverging from the rebound.

Expected impact

Could stabilize if broader risk-on continues; otherwise may lag.

Evidence & confidence

No company-specific information beyond the price move.

$ICLBearishLow confidence
Context

ICL fell 1.49% as Tower Semiconductor and other names declined while the broader market recovered.

Expected impact

Choppy near-term; watch for correlation with regional risk headlines.

Evidence & confidence

The article provides no ICL-specific news beyond the price move.

Market effects

Insurance strength (Insurance Index +2.2%) and divergence in defense/industrial names suggest sector rotation tied to regional risk sentiment.

Tel Aviv indices recovered after US pressure led Israel and Iran to cease hostilities, improving near-term risk appetite.

Limited direct global spillover in the text; primarily a regional risk-sentiment read-through.

Counterpoint

The rebound may be headline-driven and therefore fragile; single-name divergence (e.g., TSEM -4.73%) hints at positioning/sector flows beyond the macro de-escalation story.

Key entities

  • Tel Aviv Stock Exchange

    Indices recovered from early losses after cease-hostilities clarity between Israel and Iran.

  • Israel and Iran

    Bowed to US pressure to cease hostilities, driving risk sentiment in Tel Aviv.

Related articles

$BHCMedAI 8/10

Bausch Health Soars 21% on Beat-and-Raise Quarter: Core EBITDA Hits a “First Time” Milestone

Bausch Health (BHC) rose 21% after reporting adjusted EPS of $1.77, beating estimates, and raising its full-year outlook. Core EBITDA, excluding Bausch + Lomb, exceeded $1 billion for the first time. Xifaxan's growth and debt reduction contributed to the results. The company also anticipates a Medicare price impact on Xifaxan in 2027. AbbVie (ABBV) and Teva (TEVA) face similar challenges with their drugs. BHC's forward P/E remains below its five-year average.

$TSEMHighAI 8/10

Tower Semiconductor’s $1.2B Profit Roadmap Faces Its Biggest Test Yet in Q3 Earnings

Tower Semiconductor (TSEM) reports Q3 earnings on November 2, with shares down 21.25% in the past month. Q2 saw record revenue of $460.08M and adjusted EPS of $0.88, prompting raised 2028 targets to $3.6B revenue and $1.2B net profit. Analysts expect Q3 EPS of $1.0663 and revenue of $522.06M, with silicon photonics (SiPho) expansion and capacity timing as key focus areas.

$TEVAMed

25%–40% of patients with schizophrenia or bipolar I or II have acute agitation. Teva bought rights to a treatment under FDA review for home use.

Teva Pharmaceuticals acquired worldwide rights to BXCL501, a dexmedetomidine sublingual film under FDA review for at-home use in treating agitation linked to schizophrenia or bipolar disorders. The acquisition supports Teva's growth strategy and addresses an unmet patient need. BXCL501, if approved, would be the first FDA-approved at-home treatment for this condition. Teva aims to expand its neuroscience portfolio with this late-stage asset.

$TEVAMed

Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline

Teva Pharmaceuticals (TEVA) acquired worldwide rights to BXCL501, a dexmedetomidine sublingual film under FDA review for at-home use in treating agitation linked to schizophrenia or bipolar disorders. The deal, valued at up to $67.5M, expands Teva's neuroscience pipeline and aligns with its growth strategy. BXCL501, if approved, would be the first FDA-approved at-home treatment for this condition.